$BMRN News

BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation

U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $62

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating

Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest

BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment

BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026

BioMarin Pharmaceutical Presented New Data From Phase 2 Three-Year Extension Study Of VOXZOGO In 13 Children With Hypochondroplasia That Demonstrated Sustained Improvements In Annualized Growth Velocity And Height Standard Deviation Score

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals

Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years

BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story

BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky

BioMarin Reveals Dwarfism Study Data, Stock Soars

BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint

BioMarin (BMRN) Is Down 6.3% After Mixed Phase 3 BMN 401 Results in ENPP1 Deficiency

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

BMRN Stock Down on Mixed Results From Rare Disease Therapy Study

B of A Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80